Giant cell arteritis …

Shira S Simon MD MBA

Neuro-Ophthalmology & Neuro-Otology

Updated 09.25.2024
Released 05.14.1996
Expires For CME 09.25.2027

Giant cell arteritis

Author: Shira S Simon MD MBA

See Contributor Disclosures

Editor: Jonathan D Trobe MD

Giant cell arteritis

In This Article

Quick Link

Introduction

Overview

Giant cell arteritis, also called temporal arteritis, is the most common form of systemic vasculitis in the elderly. Its etiology is unknown. Advanced age and Caucasian race are risk factors. Giant cell arteritis can result in ophthalmologic, neurologic, and other systemic complications. When it presents with vision loss in one eye, or with diplopia, it is an ophthalmic emergency as the unaffected eye may become irreversibly involved within days if treatment is not promptly initiated. Untreated patients are also at an increased risk for stroke and other vascular events. High-dose corticosteroids are the mainstay of acute treatment. Other adjunctive immunosuppressants are also used as steroid-sparing agents for the longer-term management of this condition.

Key points

	• Giant cell arteritis, also known as temporal arteritis, is a systemic vasculitis that primarily affects the branches of the external carotid arteries, but also the large arteries of the neck, chest, and abdomen.
	• Vascular pathology consists of fracturing of the internal elastic lamina and granulomatous inflammation and thickening of the adventitia and media of medium-sized and large arteries.
	• The cephalic disease occurs almost exclusively in patients over the age of 60 years old and usually presents with headache, along with manifestations of ischemia in the tissues of the head. The chest and abdominal disease often occurs in younger patients and primarily presents with occlusion, dissection, and aneurysm of the aorta and its branches.
	• A highly specific symptom of giant cell arteritis is jaw claudication, a crescendo pain in the mandibular region evoked by chewing solid food; it results from ischemia in the temporalis and masseter muscles.
	• Vision loss is the most serious complication, resulting primarily from ischemic optic neuropathy, but also from central retinal artery and cilioretinal artery occlusion.
	• Diplopia can occur in giant cell arteritis as the result of ischemia to the ocular motor nerves or extraocular muscles.
	• Serious complications can be prevented by timely initiation of corticosteroid treatment with the possible addition of steroid-sparing agents.

Historical note and terminology

Giant cell arteritis was first described by Sir Jonathan Hutchinson in an 80-year-old patient who was unable to wear a hat due to painful red streaks over the temporal arteries. The condition was then called “arteritis of the aged” (38). A complete description of giant cell arteritis was later made by Bayard Horton and colleagues at the Mayo Clinic (36).

Another painful syndrome called polymyalgia rheumatica shares a strong predilection for the elderly (05). In the mid-1950s giant cell arteritis and polymyalgia rheumatica were conceived as manifestations of the same disease (65). An autopsy study linked polymyalgia rheumatica to giant cell arteritis of the aorta and its main branches (28; 63), and a meta-analysis found that concurrent giant cell arteritis and polymyalgia rheumatica diagnoses are not infrequent across the literature (61). A term that formally combines the two diseases is “giant cell arteritis–polymyalgia rheumatica spectrum disease” (GPSD) (85).

Clinical manifestations

Presentation and course

Diagnostic criteria. According to the American College of Rheumatology 2022 criteria, patients with giant cell arteritis must be aged 50 years or older at diagnosis and have a cumulative score of 6 or more points across the following 10 items (66):

	• positive temporal artery biopsy or temporal artery halo sign on ultrasound (+5);
	• erythrocyte sedimentation rate ≥50 mm/hr or C reactive protein ≥10 mg/L (+3);
	• sudden visual loss (+3);
	• morning stiffness in shoulders or neck, jaw or tongue claudication, new temporal headache, scalp tenderness, temporal artery abnormality on vascular examination, bilateral axillary involvement on imaging (angiography, ultrasound, or FDG-PET), and FDG uptake throughout the aorta on FDG-PET/CT (+2 each)

Non-ophthalmic manifestations. Giant cell arteritis can affect both the head (more medium-sized) vessels as well as the trunk (larger) vessels and manifest with various respective symptoms.

Headache has been reported in up to 70% to 80% of patients (79), reinforcing the fact that the absence of headache does not preclude this diagnosis. Momentary stabbing or ice pick headache accompanying new-onset persistent headache in an elderly person may also be an indicator of giant cell arteritis (73).

Diffuse tenderness and ulceration of the scalp, face, or oral mucosa results from ischemia secondary to widespread arteritic involvement of extracranial vessels. In elderly patients, these signs strongly suggest giant cell arteritis. Patients should be asked if they are experiencing new tenderness when they comb their hair, or if a hat or the temple portion of their glasses is causing new sensitivity to touch there. Scalp ulceration and necrosis may also result from external carotid artery ischemia but is often misdiagnosed as a herpes zoster infection. Lingual ischemia and necrosis from arteritis of the lingual artery, the first branch of the external carotid artery, have also been associated with giant cell arteritis (12) but are often misdiagnosed as glossitis.

Abnormalities of the temporal artery include prominence, irregular contour, tenderness, and a diminished or absent pulse (51).

Jaw claudication is virtually pathognomonic of giant cell arteritis. Because of collateral flow, both internal and external carotid artery systems must be affected to produce this symptom. It must be distinguished from other causes of pain in the lower face and oral cavity. The pain of jaw claudication builds progressively with chewing, owing to ischemia in the domain of the maxillary artery, which supplies the masseter muscles. In contrast, dental pain can occur even with the first bite and with any jaw movement, secondary to pathology in the temporomandibular joint. One proposed method of evaluating for jaw claudication is the “chewing gum test.” Patients are asked to chew gum for several minutes at a rate of one chew per second. A delay in the onset of jaw pain of 2 minutes suggests claudication (47). As with claudication elsewhere, the pain is relieved with rest and usually requires several seconds to dissipate after chewing ceases.

Other non-ophthalmic manifestations of giant cell arteritis include recent-onset fever, leukocytosis, anemia, depression, fatigue, and weight loss. These nonspecific constitutional symptoms are often dismissed by patients and their caregivers as natural consequences of aging. Lower back pain can be the presenting symptom of abdominal aortic arteritis, a finding identifiable on FDG-PET scan (22; 45).

Ophthalmic manifestations. According to a large review, vision loss occurs in one third to one half of patients with giant cell arteritis (25). It is usually monocular at outset and often preceded by non-ophthalmic symptoms by weeks to months. Multiple attacks of transient monocular vision loss typically occur ahead of persistent vision loss. Transient or constant diplopia, a sign of ischemia of oculomotor nerves or extraocular muscles, may occur as an isolated manifestation or precede vision loss (09). Up to 20% of patients can present with vision loss without any other systemic symptoms (“occult giant cell arteritis”) (11).

Vision loss in the initially unaffected eye typically develops within days to weeks of the first eye’s involvement. The goal of timely therapy is to prevent vision loss in that eye and to minimize the extent of vision loss in the initially affected eye.

The most common cause of vision loss in giant cell arteritis is ischemic optic neuropathy. Ophthalmoscopic examination of the affected eye reveals optic disc swelling, often pallid because of extreme infarction. The ischemia derives from reduced perfusion in the posterior ciliary arteries. Very rarely, the optic disc may appear normal on ophthalmoscopy.

An alternative cause of vision loss in giant cell arteritis is central retinal artery or cilioretinal artery occlusion. In central retinal artery occlusion, ophthalmoscopy will disclose a “cherry red spot,’’ or retinal whitening around the fovea with central preservation of its reddish color. The simultaneous occurrence of ischemic optic neuropathy and central retinal artery occlusion in the same eye or in the fellow eye is held to be pathognomonic of giant cell arteritis (31; 37). Cilioretinal artery occlusion will appear as a patch of retinal whitening extending from the optic disc toward the fovea. In such cases, visual acuity may be preserved, but the visual field will be abnormal.

Polymyalgia rheumatica. Polymyalgia rheumatica, like giant cell arteritis, almost exclusively affects individuals over the age of 50 years. Common presenting symptoms include pain and stiffness in the shoulder or pelvic girdles. Pain and limited motion of the axial skeleton, including the cervical and thoracic spine, are also common. Pain and stiffness are often worse on rising in the morning, with some improvement in mobility as the day proceeds. Onset may be insidious or acute. Severity of symptoms can be asymmetric, but the disorder is invariably bilateral. There may be mild swelling of the shoulders and distal joints in the extremities, but there are no visible articular deformities. Polymyalgia rheumatica may have a range of atypical presentations, including peripheral synovitis, mild weakness, and a normal sedimentation rate. The duration of polymyalgia rheumatica symptoms has ranged from 6 months to as long as 14 years in patients who have developed the clinical manifestations of giant cell arteritis.

Prognosis and complications

Visual loss is irreversible. Relapses in non-ophthalmic manifestations are more frequent than relapses in ophthalmic manifestations. They are said to occur in half of treated patients, most often within the first 2 years of diagnosis. The rate of relapse is more often related to an abbreviated duration of steroid therapy than to the initial dose (34; 54). In patients with relapses, the time required to achieve maintenance prednisone dosages was significantly longer, and the cumulative prednisone dose required during the first treatment year was significantly higher in comparison to those without relapse (01; 03).

There is no consistently documented decrease in life expectancy in giant cell arteritis compared to age-matched controls (56; 07; 06). The exceptions are patients who have developed aortic dissection, which markedly increases mortality (62). Death attributed to complications of giant cell arteritis is rare but has been reported from vertebral artery occlusion and myocardial infarction (80). In one study, prophylactic statin treatment reduced the incidence of cardiovascular hospitalizations (69).

The incidence of aortic aneurysm is dramatically increased in giant cell arteritis. Hypertension and polymyalgia rheumatica with a marked inflammatory response at the time of diagnosis were the most predictive characteristics for later development of aortic disease (24). Surgical repair of arteritic aortic aneurysms can be carried out successfully (04; 86).

Clinical vignette

A 78-year-old woman presented with a 2-month history of malaise, poor appetite, and unintentional weight loss. During the previous few weeks, she experienced frequent severe vertex headaches that awoke her from sleep. She experienced scalp pain when combing her hair.

A dentist who was consulted for jaw pain found no dental cause. On further questioning, she specified that the pain in her jaw would start around 1 minute after she began to chew solid food and grow in severity over the following minute to the point that she would have to stop chewing. When she stopped chewing, the jaw pain would subside after 15 to 20 seconds. She reported pain in her hips and stiffness of her legs that made walking difficult.

On the day of her office visit, she recalled a recent 1-minute episode of seeing a “shade pulled down over my left eye.”

Examination revealed a frail-looking elderly woman in mild distress. There was evidence of recent weight loss, and she had difficulty rising from the waiting room chair. Blood pressure was 180/95 in the right arm and 140/80 in the left arm. There was a loud left subclavian bruit. An ulcer was noted in the buccal mucosa next to the left lower teeth. There were no localizing findings on neurologic examination. Her gait appeared painful and stiff, and she held her head rigidly in the straight-ahead position as she walked. When attempting to bend her neck forward to either side, she winced with pain. The examiner was able to move her head and neck in all directions passively, but it required slow and steady movement to minimize pain. Active and passive flexion of either leg caused pain in the hips and upper thighs.

Visual acuity was 20/20. There was no subjective red desaturation with either eye on viewing a red bottle cap. Visual fields were full on confrontation testing. The eyes had normal excursions and were aligned. Pupils were normal in size and reactivity. Ophthalmoscopy was normal.

Complete blood count revealed moderate normochromic, normocytic anemia, and the Westergren erythrocyte sedimentation rate was 89 mm/hr. Carotid duplex blood flow examination showed insignificant stenosis on either side, but ocular pneumoplethysmography showed reduced pulse amplitude in both eyes. Based on a presumptive diagnosis of giant cell arteritis, intravenous methylprednisolone 1 gram daily was initiated for 3 days.

Temporal artery biopsy revealed areas of intimal proliferation and fragmentation of the internal elastic lamina. Adjacent to disrupted segments of the elastic lamina, the media was infiltrated with lymphocytes, plasma cells, epithelioid cells, and multinucleated giant cells. These findings were interpreted as consistent with active giant cell arteritis.

The patient was discharged on prednisone 1 mg/kg/day. Within 48 hours of treatment initiation, she was free of pain, and within 2 weeks her body weight and strength had nearly recovered to premorbid status. After 1 month of steroid therapy, the prednisone dosage was slowly tapered in decrements of 5 mg each month.

During follow-up of 2 years, the steroid dose was eventually tapered off without clinical consequences. The potentially dire consequences of giant cell arteritis were averted by early diagnosis and treatment.

Differential diagnosis

Confusing conditions

In older patients with transient vision loss, giant cell arteritis should be in the differential diagnosis. Once persistent vision loss has occurred from ischemic optic neuropathy or retinopathy, the differential diagnosis includes non-arteritic ischemic optic neuropathy (NAION), infection, cancerous infiltration, compression by mass lesions, and alternative inflammatory conditions, such as myelin oligodendrocyte glycoprotein antibody disorder and neuromyelitis optica spectrum disorder.

The principal challenge is to distinguish giant cell arteritis from NAION. NAION typically occurs in patients over the age of 40 with an arteriosclerotic profile that predisposes to small vessel disease. Patients with NAION lack the non-ophthalmic manifestations of giant cell arteritis and polymyalgia rheumatica. Visual loss is less profound than in giant cell arteritis and is not usually preceded by transient vision loss episodes. Optic disc swelling is less pallid, and the optic discs usually have a small cup-to-disc ratio. There should be no evidence of retinal ischemia. MRI will disclose no abnormalities of the optic nerves except enhancement of the affected optic disc and sometimes ischemic cerebral white matter focal signal abnormalities. NAION is usually unprovoked but may also occur after an episode of systemic hypotension, middle fossa irradiation, neurosurgery, cardiac surgery, or prone position spine surgery.

Associated or underlying disorders

Giant cell arteritis may occasionally be part of a panuveitis (70) or an orbital inflammatory syndrome that presents with diplopia, mildly reduced ocular excursions, and periocular pain (15). It has been documented as the most common cause of fever of unknown origin in the elderly (84). Large artery giant cell arteritis may present with ascending aortic aneurysm (27) or as subclavian artery stenosis (76).

Diagnostic workup

The most frequently used tests in the diagnostic workup of giant cell arteritis include Westergren erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), complete blood count, and temporal artery biopsy. Mild anemia is common, as are various degrees of leukocytosis, sometimes with a left shift, as well as thrombocytosis.

Marked elevation of ESR is the most common laboratory abnormality, but it is nonspecific. In one study, the laboratory criteria most strongly suggestive of giant cell arteritis were CRP above 2.45 mg/dl and ESR of 47 mm/hr or more. CRP was more sensitive (100%) than ESR (92%) for detection of giant cell arteritis. The combination of ESR and CRP above the cutoff values gave the best specificity (97%) (32). However, a normal ESR or CRP does not rule out giant cell arteritis when other features are highly suggestive.

The ESR in giant cell arteritis and polymyalgia rheumatica is often greater than 100 mm/hr. Other rheumatologic disorders, stroke, coronary artery disease, renal disease, and cancer may also elevate ESR to that degree. Accordingly, studies have sought to identify more distinct biological markers of clinical activity and to differentiate giant cell arteritis from other rheumatological disorders. Elevation of anticardiolipin antibodies was found in approximately 50% of patients with giant cell arteritis and polymyalgia rheumatica. There was no significant correlation between the presence of antiphospholipid antibody and ischemic events (21).

Biopsy remains the gold standard in the diagnosis of giant cell arteritis. The pathology consists of a granulomatous inflammatory reaction concentrated at the innermost part of the vascular media near zones of fragmented and reduplicated internal elastic lamina with adjacent intimal proliferation, at times leading to complete occlusion of the lumen. Giant cells are, however, not necessary for the diagnosis.

There are many cases of active giant cell arteritis in which an entire temporal artery or segments of the artery are not involved—so-called “skip lesions” (43). To compensate for the patchy nature of the pathologic process, both the American College of Rheumatology and British Society for Rheumatology suggest a “long-segment biopsy” of at least 1 cm (52; 57). Although it has been standard practice, the pathologic examination of a temporal artery specimen at multiple levels does not increase the diagnostic yield of the test. The authors recommend that such examination be reserved for cases with high clinical suspicion if initial inspection is negative (10).

The issue of whether to biopsy one or both temporal arteries remains controversial. In a large 2010 survey of U.S. ophthalmologic subspecialists, 61% favored initial unilateral temporal artery biopsy; 18% favored bilateral biopsy; and 16% favored bilateral biopsy only if one biopsy was negative but clinical suspicion was high (77). Rheumatologists were 4.5 times more likely to favor initial bilateral biopsy than ophthalmologists. Most respondents believed that biopsy results would have high diagnostic accuracy if performed within 2 weeks of starting corticosteroid treatment.

The consensus opinion is that each physician must contextualize negative biopsy results based on the degree of clinical suspicion, the adequacy of the specimen, and the degree to which the biopsy material is pathologically examined. Most authorities also agree that if clinical suspicion is high enough, patients should be treated even in the face of a negative biopsy in one temporal artery or both.

Because there is also the possibility of false negatives with temporal artery biopsies and this testing requires a surgical procedure, alternatives have been explored. A low score on a giant cell arteritis risk calculator, or multivariate prediction model, is proposed as a way to decrease the need for a biopsy (40; 41). This model has been validated for the following variables: age, gender, new-onset headache, clinical temporal artery abnormality, jaw claudication, ischemic vision loss, diplopia, CRP, and platelet count.

Temporal and axillary artery ultrasound, MRI, MR angiography (MRA), and PETCT are frequently used in place of biopsy or as adjuncts to it (29). The diagnostic sonographic sign of giant cell arteritis is a noncompressible hyperechoic wall signal (“halo sign”) secondary to thickening of the intima-media complex of the superficial temporal or axillary arteries (42; 67). The European League Against Rheumatism (EULAR) includes temporal artery and axillary artery ultrasound as a diagnostic guideline (16). However, ultrasound results continue to show a sensitivity range between 9% and 100% and a specificity range from 66% to 100%, perhaps reflecting differences in case selection and sonographic skill and technique (13; 33; 60).

MRI and FDG-PET are alternative diagnostic tools. Vascular wall inflammation causes increased vessel wall thickness and mural enhancement (08). Temporal artery MRI and FDG-PET have been gradually adopted in clinical practices and included in the European League Against Rheumatism (EULAR) guideline as an alternative in cases in which ultrasound is not available or is inconclusive (17; 16; 68). The diagnostic accuracy of 3D T1-weighted (“black-blood”) MRI was deemed adequate in the diagnosis of giant cell arteritis (72; 90). A European multicenter prospective study found contrast-enhanced MRI of superficial temporal arteries to be 78.4% sensitive and 90.4% specific in diagnosing giant cell arteritis. Diagnostic accuracy declined after 5 days of steroid treatment (44). A meta-analysis reported a pooled sensitivity of 73% and a specificity of 88% for MRI diagnosis of giant cell arteritis (19). Another study found high-resolution MRI and color-coded duplex ultrasonography of the temporal arteries to be more sensitive than temporal artery biopsy in diagnosing giant cell arteritis and that sensitivity rapidly declined during the first few days after initiation of steroid treatment (30).

Large vessel involvement is present in up to 80% of patients with giant cell arteritis (46). Because of the predominantly large-vessel involvement, patients may present with a negative temporal artery biopsy. CT or MR angiography (MRA) is the diagnostic procedure of choice for suspected large vessel arteritis in giant cell arteritis. MRA of large vessel walls normalized in only one third of the patients who had sustained clinical and laboratory remission (71).

A prospective double-blind, cross-sectional study evaluated the diagnostic accuracy of positron emission tomography/computed tomography (PET/CT) of the head, neck, and chest for determining a diagnosis of giant cell arteritis (75). Compared to temporal artery biopsy, the sensitivity of PET/CT was 92% and specificity was 85%. The negative predictive value was 98%. Compared to clinical diagnosis, PET/CT had a sensitivity of 71% and specificity of 91%. The authors suggested that the high diagnostic accuracy of a PET/CT protocol would support its use as a first-line test for giant cell arteritis. They also concluded that PET/CT had benefit over temporal artery biopsy in detecting aortitis as well as imitators of vasculitis.

Algorithms incorporating multiple imaging modalities may achieve higher sensitivity and specificity for the diagnosis of giant cell arteritis. MRI, MRA, FDG-PET, and PET/CT for both large vessel and cranial artery evaluation can be performed based on availability and cost. In cases of visual loss or diplopia, fluorescein angiography can demonstrate involvement of multiple vascular territories in support of a diagnosis of giant cell arteritis. Other techniques to evaluate choroidal blood flow noninvasively, including optical coherence tomographic angiography, are in development (53).

Management

The standard recommendation for initial treatment of patients without ophthalmic signs is to initiate prednisone at a dosage of 40 to 80 mg/day. This dose is usually maintained for 3 to 4 weeks and then gradually reduced over months, together with monitoring for reemergence of headache, jaw claudication, and other less specific symptoms, or rising levels of ESR and CRP. Sometimes side effects require that the dose be reduced earlier. For polymyalgia rheumatica without signs of giant cell arteritis, patients can be safely managed with prednisone 15 mg/day or less from the outset. They seem to be at low risk for ischemic complications (14).

For patients with vision loss or diplopia attributable to giant cell arteritis, intravenous pulse methylprednisolone therapy is often initiated at 1 gm/day. This is supported by the results of a randomized placebo-controlled study that demonstrated sustained remissions and a lower median daily dose of prednisone at 78 weeks after treatment onset among patients who received intravenous methylprednisolone at 15 mg/kg of ideal body weight per day (58).

Based on clinical manifestations, giant cell arteritis may remain active for at least 1 year after diagnosis and even for an average of 3 to 4 years (48). Therefore, tapering prednisone too early commonly results in recurrence of headache and other symptoms that herald possible ischemic complications. Oftentimes it requires multidisciplinary input to best determine if vague symptoms reflect a recurrence as well. Once confirmed as a recurrence, symptoms can usually be managed by reestablishing the original high dose of steroid therapy, followed by another tapering interval, with close monitoring. This approach is, however, cumbersome and does not provide guaranteed protection from ischemic complications. It is, therefore, preferable to taper slowly and maintain a low corticosteroid or steroid-sparing dose for more than 1 year to avoid reactivation of the disease. Alternate-day steroid therapy is not sufficiently protective.

Long-term steroid therapy is not without significant side effects. One of the most serious complications is osteoporosis. Various authors have recommended prophylactic treatment for osteoporosis with calcium and phosphate compounds, but there has been little proof of their effectiveness. In one report, the risks of diabetes mellitus and bone fracture were two to five times greater among patients treated for polymyalgia rheumatica than among untreated age-matched subjects (23). Proportional hazards modeling showed that the following three factors independently increased the number of adverse events: (1) advanced age at diagnosis, (2) cumulative dose of prednisone at least 1800 mg, and (3) female sex. Treatment should include antibiotic prophylaxis against Pneumocystis jirovecii pneumonia (PCP).

There has been interest in adding immunomodulatory drugs to the treatment regimen to reduce steroid dose requirements. The beneficial effects of tocilizumab, an IL-6 inhibitor, as a corticosteroid-sparing intervention was first demonstrated in 2016 (89; 83). A subsequent prospective trial studied the efficacy of tocilizumab as an adjuvant treatment to systemic corticosteroids in 251 patients with newly diagnosed or relapsing giant cell arteritis (83). The tocilizumab groups had lower cumulative median prednisone doses relative to the placebo group. Serious adverse events were also less common in the tocilizumab groups. A contraindication to starting tocilizumab therapy is a history of diverticulitis, which would predispose to intestinal perforation. In 2017, tocilizumab became the first FDA-approved medication to treat giant cell arteritis (83). A retrospective, single-center analysis found that tocilizumab improved clinical symptoms, including vision loss, in patients with giant cell arteritis and polymyalgia rheumatica (87; 88). The adverse events attributed to corticosteroids were comparable before and after tocilizumab treatment.

The combination of tocilizumab and a prednisone taper was effective in maintaining clinical remission in the Giant Cell Arteritis Actemra (GiACTA) trial (81). In an open-label extension phase of the GiACTA trial, 42% of patients remained in remission without need for tocilizumab or corticosteroids 2 years after tocilizumab cessation (82). However, the study also concluded that for patients who experience relapse, it is important to include prednisone in treatment to prevent further vision loss. The long-term effect of adding tocilizumab in the treatment of giant cell arteritis remains under study (02).

Other immunomodulatory agents have not emerged as useful in the treatment of giant cell arteritis. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate for the treatment of giant cell arteritis did not demonstrate benefit (35). Cyclophosphamide and azathioprine, studied in small cohorts of patients for their effectiveness as steroid-sparing agents, have been of uncertain benefit (50). Etanercept, a tissue necrosis factor inhibitor, reduced the cumulative dose of corticosteroid required to keep giant cell arteritis in clinical remission over the course of a 1-year period, but the contribution of etanercept did not reach statistical significance (55).

In giant cell arteritis involving large arteries, new therapeutic approaches are being sought for the steroid-resistant inflammatory process, possibly involving manipulation of specific inflammatory cytokines and other inflammatory mediators. A prospective study of 25 patients with biopsy-proven giant cell arteritis demonstrated plasma interleukin-6 (IL-6) to be a much more sensitive measure of disease activity than ESR (91).

Outcomes

See prognosis and complications.

References

01: Alba MA, Garcia-Martinez A, Prieto-Gonzalez S, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore) 2014;93(5):194-201. PMID 25181312
02: Alba MA, Kermani TA, Unizony S, et al. Relapses in giant cell arteritis: updated review for clinical practice. Autoimmun Rev 2024;23(6):103580. PMID 39048072
03: Albrecht K, Huscher D, Buttgereit F, et al. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. Rheumatol Int 2018;38(4):569-77. PMID 29124397
04: Atluri P, Woo YJ. High-risk repair of ascending aortic aneurysm due to giant cell aortitis. Asian Cardiovasc Thorac Ann 2007;15(3):252-4. PMID 17541000
05: Barber HS. Myalgic syndrome with constitutional effects. Polymyalgia rheumatica. Ann Rheum Dis 1957;16:230-7. PMID 13445065
06: Ben-Shabat N, Tiosano S, Shovman O, et al. Mortality among patients with giant cell arteritis: a large-scale population-based cohort study. J Rheumatol 2020;47(9):1385-91. PMID 31839591
07: Brekke LK, Fevang BS, Diamantopoulos AP, Assmus J, Esperø E, Gjesdal CG. Survival and death causes of patients with giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study. Arthritis Res Ther 2019;21(1):154. PMID 31238961
08: Bley TA, Wieben O, Uhl M, et al. Integrated head-thoracic vascular MRI at 3T: assessment of cranial, cervical and thoracic involvement of giant cell arteritis. MAGMA 2005;18:193-200. PMID 16133594
09: Castillejo Becerra CM, Crowson CS, Koster MJ, Warrington KJ, Bhatti MT, Chen JJ. Population-based rate and patterns of diplopia in giant cell arteritis. Neuroophthalmology 2021;46(2):75-9. PMID 35273408
10: Chakrabarty A, Franks AJ. Temporal artery biopsy: is there any value in examining biopsies at multiple levels. J Clin Pathol 2000;53(2):131-6. PMID 10767829
11: Chen JJ, Leavitt JA, Fang C, Crowson CS, Matteson EL, Warrington KJ. Evaluating the incidence of arteritis ischemic optic neuropathy and other causes of vision loss from giant cell arteritis. Ophthalmology 2016;123(9):1999-2003. PMID 27297405
12: Cho YM, El Khoury L, Paramo J, et al. Tongue necrosis secondary to giant cell arteritis, successfully treated with tocilizumab: a case report. BMC Musculoskelet Disord 2023;24(1):382. PMID 37189114
13: Chrysidis S, Duftner C, Dejaco C, et al. Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group. RMD Open 2018 May 17;4(1):e000598. PMID 29862043
14: Cimmino MA, Parodi M, Montecucco C, Caporali R. The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity. BMC Musculoskelet Disord 2011;12(1):94. PMID 21569559
15: de Heide LJ, Talsma MA. Giant-cell arteritis presenting as an orbital pseudotumor. Neth J Med 1999;55:196-8. PMID 10555437
16: Dejaco C, Ramiro S, Bond M, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis 2024;83(6):741-51. PMID 37550004
17: Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 2018;77:636-43. PMID 29358285
18: Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010;121(7):906-15. PMID 20142449
19: Duftner C, Dejaco C, Sepriano A, Falzon L, Schmidt WA, Ramiro S. Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: A systematic literature review and meta-analysis informing the EULAR recommendations. RMD Open 2018;4:e000612. PMID 29531788
20: Esen I, Jiemy WF, van Sleen Y, et al. Functionally heterogenous macrophage subsets in the pathogenesis of giant cell arteritis: novel targets for disease monitoring and treatment. J Clin Med 2021;10(21):4958. PMID 34768479
21: Espinosa G, Tassies D, Font J, et al. Antiphospholipid antibodies and thrombophilic factors in giant cell arteritis. Semin Arthritis Rheum 2001;31(1):12-20. PMID 11503135
22: Fernandez-Lopez MJ, Wamen S, Karmali R, Peretz A, Gonzalez-Gay MA, Bentin J. Low back pain as presenting manifestation of giant cell arteritis associated to abdominal aortitis. Clin Exp Rheumatol 2007;25(1 Suppl 44):S31-3. PMID 17428361
23: Gabriel SE, Espy M, Erdman DD, Bjornsson J, Smith TF, Hunder GG. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. Arthritis Rheum 1999;42:1255-8. PMID 10366119
24: Gonzalez-Gay MA, Garcia-Porrua C, Pineiro A, Pego-Reigosa R, Llorca J, Hunder GG. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore) 2004;83(6):335-41. PMID 15525845
25: Goodwin JA. Temporal arteritis. In: Vinken PJ, Bruyn GW, Klawans HL, editors. Neurological manifestations of systemic diseases. Part II. New York: North-Holland, 1980:313-42.
26: Gran JT, Myklebust G. The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987-94. J Rheumatol 1997;24(9):1739-43. PMID 9292797
27: Hamano K, Gohra H, Katoh T, et al. An ascending aortic aneurysm caused by giant cell arteritis: report of a case. Surg Today 1999;29:957-9. PMID 10489146
28: Hamrin B. Polymyalgia arteritica with morphological changes in the large arteries. Acta Med Scand 1972;533(Suppl):4-164.
29: Hansen MS, Terslev L, Jensen MR, et al. Comparison of temporal artery ultrasound versus biopsy in the diagnosis of giant cell arteritis. Eye 2023;37:344-9. PMID 35094027
30: Hauenstein C, Reinhard M, Geiger J, et al. Effects of early corticosteroid treatment on magnetic resonance imaging and ultrasonography findings in giant cell arteritis. Rheumatology (Oxford) 2012;51(11):1999-2003. PMID 22772317
31: Hayreh SS. Giant cell arteritis: Its ophthalmic manifestations. Indian J Ophthalmol 2021;69(2):227-35. PMID 33463564
32: Hayreh SS, Podhajsky PA, Raman R, Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. [Comments]. Am J Ophthalmol 1997;123(3):285-96.** PMID 9063237
33: He J, Williamson L, Ng B, et al. The diagnostic accuracy of temporal artery ultrasound and temporal artery biopsy in giant cell arteritis: A single center Australian experience over 10 years. Int J Rheum Dis 2022;25(4):447-53. PMID 35064750
34: Hoffman GS. Giant cell arteritis. Ann Intern Med 2016;165(9):ITC65-80. PMID 27802475
35: Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46(5):1309-18. PMID 12115238
36: Horton BT, Magath TB, Brown GE. An undescribed form of arteritis of the temporal vessels. Proc Mayo Clin 1932;7:700-1.
37: Huang D, Liu Y, Hacein-Bey L, Moussa K. Combined central retinal artery and medial posterior ciliary artery occlusion: Localizing the lesion. Am J Ophthalmol Case Rep 2023;30:101823. PMID 36874357
38: Hutchinson J. Diseases of the arteries. Arch Surg 1890;1:323-33.
39: Idowu AB, Khandwala P, Tan IJ. Race and gender on the mortality of giant cell arteritis in hospitalized patients: a 15-year national inpatient study. Cureus 2023;15(9):e46165. PMID 37905266
40: Ing EB, Lahaie Luna G, Toren A, et al. Multivariable prediction model for suspected giant cell arteritis: development and validation. Clin Ophthalmol 2017;11:2031-42. PMID 29200816
41: Ing EB, Miller NR, Nguyen A, et al. Neural network and logistic regression diagnostic prediction models for giant cell arteritis: development and validation. Clin Ophthalmol 2019;13:421-30. PMID 30863010
42: Kirby C, Flood R, Mullan R, Murphy G, Kane D. Evolution of ultrasound in giant cell arteritis. Front Med (Lausanne) 2022;9:981659. PMID 36262280
43: Klein RG, Campbell RJ, Hunder GG, Carney JA. Skip lesions in temporal arteritis. Proc Mayo Clin 1976;51:504-10. PMID 950804
44: Klink T, Geiger J, Both M, et al. Giant cell arteritis: diagnostic accuracy of MR imaging of superficial cranial arteries in initial diagnosis-results from a multicenter trial. Radiology 2014;273(3):844-52. PMID 25102371
45: Koizumi N, Takasugi J, Ohara N, Kawamoto M. FDG-PET/CT of giant cell arteritis with normal inflammatory markers. Ann Neurol 2022;92(2):337-9. PMID 35668652
46: Koster MJ, Matteson EL, Warrington KJ. Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology (Oxford) 2018;57(Suppl_2):ii32-42. PMID 29982778
47: Kuo CH, McCluskey P, Fraser CL. Chewing gum test for jaw claudication in giant-cell arteritis. N Engl J Med 2016;374(18):1794-5. PMID 27144869
48: Kyle V, Hazleman BL. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 1993;52:847-50. PMID 8311533
49: Lie JT. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum 1990;33(8):1074-87. PMID 1975173
50: Loock J, Henes J, Kotter I, et al. Treatment of refractory giant cell arteritis with cyclophosphamide: a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol 2012;30(1 Suppl 70):S70-6. PMID 22640650
51: Lyons HS, Quick V, Sinclair AJ, Nagaraju S, Mollan SP. A new era for giant cell arteritis. Eye (Lond) 2020;34(6):1013-26. PMID 31582795
52: Mackie SL, Dejaco C, Appenzeller S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology (Oxford) 2020;59(3):e1-e23. PMID 31970405
53: Mahdjoubi A, Haouas M, Caliot J, et al. Optical coherence tomography angiography of macula in chronic anterior ischaemic optic neuropathy associated with giant cell arteritis. Neuroophthalmology 2018;43(3):192-5. PMID 31312244
54: Mainbourg S, Addario A, Samson M, et al. Prevalence of giant cell arteritis replase in patients treated with glucocorticoids: a meta-analysis. Arthritis Care Res (Hoboken) 2020;70(6):838-49. PMID 30951256
55: Martinez-Taboada VM, Rodriguez-Valverde V, Carreno L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008;67(5):625-30. PMID 18086726
56: Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med 1996;100:193-6. PMID 8629654
57: Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of giant cell arteritis and takayasu arteritis. Arthritis Rheumatol 2021;73(8):1349-65. PMID 34235884
58: Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006;54(10):3310-8. PMID 17009270
59: Nagel MA, Khmeleva N, Boyer PJ, Choe A, Bert R, Gilden D. Varicella zoster virus in the temporal artery of a patient with giant cell arteritis. J.Neurol.Sci 2013;335(1-2):228-30. PMID 24125020
60: Nakajima E, Moon FH, Junior NC, et al. Accuracy of Doppler ultrasound in the diagnosis of giant cell arteritis: a systematic review and meta-analysis. Adv Rheumatol 2023;63(1):5. PMID 36755336
61: Nielsen AW, Frølund LL, Våben C, et al. Concurrent baseline diagnosis of giant cell arteritis and polymyalgia rheumatica - a systematic review and meta-analysis. Semin Arthritis Rheum 2022;56:152069. PMID 35858507
62: Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003;48(12):3532-7. PMID 14674005
63: Ostberg G. On arteritis with special reference to polymyalgia arteritica. Acta Pathol Microbiol Scand 1973;237:1-59. PMID 4151114
64: Ostrowski RA, Metgud S, Tehrani R, Jay WM. Varicella zoster virus in giant cell arteritis: a review of current medical literature. Neuroophthalmology 2019;43(3):159-70. PMID 3131224
65: Paulley JW, Hughes JP. Giant-cell arteritis, or arteritis of the aged. Br Med J 1960;2:1562-7. PMID 13733499
66: Ponte C, Grayson PC, Robson JC, et al. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis 2022;81(12):1647-53. Erratum in: Ann Rheum Dis 2023;82(2):e52. PMID 36351706
67: Pouncey AL, Yeldham G, Magan T, Lucenteforte E, et al. Halo sign on temporal artery ultrasound versus temporal artery biopsy for giant cell arteritis. Cochrane Database Syst Rev 2024;2(2):CD013199. PMID 38323659
68: Prieto-Pena D, Castañeda S, Martínez-Rodríguez I, Atienza-Mateo B, Blanco R, González-Gay MA. Imaging tests in the early diagnosis of giant cell arteritis. J Clin Med 2021;10(16):3704. PMID 34442002
69: Pugnet G, Sailler L, Fournier JP, Bourrel R, Montastruc JL, Lapeyre-Mestre M. Predictors of cardiovascular hospitalization in giant cell arteritis: effect of statin exposure. A French population-based study. J Rheumatol 2016;43(12):2162-70. PMID 27585686
70: Rajesh CV, Cole M. Panuveitis as a presenting feature of giant cell arteritis [letter]. Br J Ophthalmol 2000;84:340. PMID 10744385
71: Reichenbach S, Adler S, Bonel H, et al. Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis. Rheumatology 2018;57(6):982-6. PMID 29529280
72: Rodriguez-Regent C, Ben Hassen W, Seners P, Oppenheim C, Régent A. 3D T1-weighted black-blood magnetic resonance imaging for the diagnosis of giant cell arteritis. Clin Exp Rheumatol 2020;38 Suppl 124(2):95-8. PMID 32301421
73: Rozen TD. Brief Sharp Stabs of Head Pain and Giant Cell Arteritis. Headache 2010;50(9):1516-9. PMID 20561065
74: Sammel AM, Smith S, Nguyen K, et al. Assessment for varicella zoster virus in patients newly suspected of having giant cell arteritis. Rheumatology (Oxford) 2020;59(8):1992-6. PMID 31776576
75: Sammel AM, Hsiao E, Schembri G, et al. Diagnostic accuracy of positron emission tomography/computed tomography of the head, neck, and chest for giant cell arteritis: a prospective, double-blind, cross-sectional study. Arthritis Rheumatol 2019;71(8):1319-28.** PMID 30848549
76: Sato M, Takeda A, Hagiwara S, et al. Giant cell arteritis and polymyalgia rheumatica presenting as subclavian artery obstruction. Ryumachi 1993;33:330-4. PMID 8235915
77: Schallhorn J, Haug SJ, Yoon MK, Porco T, Seiff SR, McCulley TJ. A national survey of practice patterns: temporal artery biopsy. Ophthalmology 2013;120(9):1930-4. PMID 23622876
78: Sharma A, Mohammad AJ, Turesson C. Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: a systematic literature review. Semin Arthritis Rheum 2020;50(5):1040-8. PMID 32911281
79: Sharma TL. Common primary and secondary causes of headaches in the elderly. Headache 2018;58(3):479-84. PMID 29322494
80: Sheehan MM, Keohane C, Twomey C. Fatal vertebral giant cell arteritis. J Clin Pathol 1993;46:1129-31. PMID 8282839
81: Spiera R, Unizony SH, Bao M, et al. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. Semin Arthritis Rheum 2021;51(2):469-76. PMID 33784598
82: Stone JH, Han J, Aringer M, et al. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the giant cell arteritis actemra (GiACTA) trial. Lancet Rheumatology 2021;3(5):E328-36. PMID 23653652
83: Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017;377(4):317-28.** PMID 28745999
84: Tal S, Guller V, Gurevich A, Levi S. Fever of unknown origin in the elderly. J Intern Med 2002; 252(4):295-304. PMID 12366602
85: Tomelleri A, van der Geest KSM, Khurshid MA, et al. Disease stratification in GCA and PMR: state of the art and future perspectives. Nat Rev Rheumatol 2023;19(7):446-59. PMID 37308659
86: Tyagi S, Safal S, Tyagi D. Aortitis and aortic aneurysm in systemic vasculitis. Indian J Thorac Cardiovasc Surg 2019;35(Suppl 2):47-56. PMID 33061066
87: Unizony SH, Bao M, Han J, Luder Y, Pavlov A, Stone JH. Treatment failure in giant cell arteritis. Ann Rheum Dis 2021a;80(11):1467-74. PMID 34049857
88: Unizony SH, McCulley TJ, Spiera R, et al. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations. Arthritis Res Ther 2021b;21(1):8. PMID 33407817
89: Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016;387(10031):1921-7.** PMID 26952547
90: Vynckier J, Demeestere J, Lambert J. Black-blood magnetic resonance imaging in giant cell arteritis. J Rheumatol 2021;48(2):301-2. PMID 33526649
91: Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000;43(5):1041-8. PMID 10817557
92: Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003;349(2):160-9. PMID 12853590

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Shira S Simon MD MBA

Dr. Simon of Northwestern University has no relevant financial relationships to disclose.
See Profile

Editor

Jonathan D Trobe MD

Dr. Trobe of the University of Michigan has no relevant financial relationships to disclose.
See Profile

Former Authors

James Goodwin MD
Peter MacIntosh MD
Omar Solyman MD
Yin Allison Liu MD PhD
Heather E Moss MD PhD

Patient Profile

Age range of presentation: 45 to 65+ years
Sex preponderance: female>male, >2:1
Heredity: heredity may be a factor
Population groups selectively affected: Caucasians
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Other giant cell arteritis: M31.6

Polymyalgia rheumatica: M35.3
ICD-11: Giant cell arteritis: 4A44.2

Polymyalgia rheumatica: FA22
OMIM: Temporal arteritis: 187360

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Giant cell arteritis

Associated Disorders

panuveitis
orbital inflammatory syndrome
ascending aortic aneurysm
subclavian artery stenosis

Differential Diagnosis

transient vision loss
non-arteritic ischemic optic neuropathy (NAION)
infection
cancerous infiltration
compression by mass lesions
- myelin oligodendrocyte glycoprotein antibody disorder
- neuromyelitis optica spectrum disorder

Also Relevant

Amaurosis fugax
Ischemic optic neuropathy
Optic neuritis
Prednisone

Clinical Categories

Patient Handouts

Polymyalgia rheumatica and giant cell arteritis

Web References

Alerts and Advisories

FDA approves Kevzara® (sarilumab) for polymyalgia rheumatica

Clinical Trials

NIH: Temporal Arteritis

Giant cell arteritis

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Autoantibodies: mechanism and testing

NF2-related schwannomatosis

Common maculopathies

Toxic and nutritional deficiency optic neuropathies

Third nerve palsy

Nystagmus

Multiple sclerosis: treatment of its symptoms

Chronic progressive external ophthalmoplegia

This is an article preview.
Start a Free Account
to access the full version.